[Articles] Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial
Phase 3positiveRetatrutidePositive
AI Analysis
Summary
Retatrutide demonstrated substantial improvements in bodyweight and glycaemic control in Phase 3 TRIUMPH-2 trial in adults with obesity and type 2 diabetes, with a safety profile consistent with other GLP-1 receptor agonists.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Retatrutide resulted in substantial improvements in bodyweight and improvements in glycaemic control with generally consistent safety profile
Importance:8/10
Sentiment:
0.85
Phase 3 DataObesityType 2 DiabetesGLP-1 AgonistWeight LossTRIUMPH-2
Related Companies
Read the original article
Published by The Lancet on September 29, 2026 10:01 PM